Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Glandular Cell Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Epithelial Neoplasm
Glandular Cell Neoplasm

Cancer Family

Glandular Cell Neoplasm

CI-CAN-00000188Explore in graph →

Non-malignant2,825 active trials43 approved drugs426 evidence items

NCIt: C7132

Overview
Statistics
Survival
Genomics166
Variants & evidence426
Drugs106
Trials10211
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (384)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 251–275 of 384 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol.
· Cancer Cell · 2003 · PMID 12559175 · validated civic_curation pubmed
Oncogenic RIT1 mutations in lung adenocarcinoma.
· Oncogene · 2014 · PMID 24469055 · validated civic_curation pubmed
HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models.
· Oncotarget · 2014 · PMID 25216528 · validated civic_curation pubmed
Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.
· Nat Med · 2013 · PMID 24162815 · validated civic_curation pubmed
PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.
· Anticancer Res · 2013 · PMID 23898052 · validated civic_curation pubmed
The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis.
· Genes Dev · 2012 · PMID 22802530 · validated civic_curation pubmed
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.
· Cancer Cell · 2004 · PMID 15324695 · validated civic_curation

Showing 251–275 of 384 publications

← Previous
1
…
10
11
12
…
16
Next →

Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.

· Mol Cancer Ther · 2012 · PMID 22294718 · validated civic_curation pubmed

Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.

· Cancer Cell · 2015 · PMID 25544636 · validated civic_curation pubmed

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.

· Nat Commun · 2019 · PMID 31399568 · validated civic_curation pubmed

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.

· EBioMedicine · 2016 · PMID 26870817 · validated civic_curation pubmed

Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors.

· PLoS One · 2007 · PMID 17726540 · validated civic_curation pubmed

Targeting Fibroblast Growth Factor Receptor (FGFR) with BGJ398 in a Gastric Cancer Model.

· Anticancer Res · 2015 · PMID 26637881 · validated civic_curation pubmed

Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer.

· Oncotarget · 2014 · PMID 25153719 · validated civic_curation pubmed

Phosphorylation of 4E-BP1 predicts sensitivity to everolimus in gastric cancer cells.

· Cancer Lett · 2013 · PMID 23340172 · validated civic_curation pubmed

Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum.

· Br J Cancer · 2012 · PMID 22343617 · validated civic_curation pubmed

Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma.

· J Cell Mol Med · 2012 · PMID 22004109 · validated civic_curation pubmed

Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment.

· Cancer Sci · 2010 · PMID 20088962 · validated civic_curation pubmed

Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status.

· Target Oncol · 2016 · PMID 26668065 · validated civic_curation pubmed

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.

· J Clin Invest · 2006 · PMID 16906227 · validated civic_curation pubmed

Overexpression of pRB in human pancreatic carcinoma cells: function in chemotherapy-induced apoptosis.

· J Natl Cancer Inst · 2002 · PMID 11792751 · validated civic_curation pubmed

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

· Cancer Res · 2008 · PMID 18829560 · validated civic_curation pubmed

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.

· Breast Cancer Res · 2009 · PMID 19874578 · validated civic_curation pubmed

Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.

· Cancer Res · 2008 · PMID 18632602 · validated civic_curation pubmed

BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.

· Mol Oncol · 2013 · PMID 23415752 · validated civic_curation pubmed